System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Sebastiano Buti, PhD is an expert in Oncology at University Hospitals Parma Medical Center (United States). As of October 2026, ScienceLeadR ranks Sebastiano Buti in the top 1% of experts worldwide for Kidney Neoplasms, Urologic Neoplasms and Carcinoma. Sebastiano Buti has authored 488 publications, the most recent in 2026, and is an investigator in 22 clinical trials, 10 of them ongoing. SLR score: 2,044 (community average: 125). How the SLR is computed.

LeadR Profile

Sebastiano Buti, PhD University Hospitals Parma Medical Center United States
2 044 ScienceLeadR Reputation 2044

Unlock

Register Login
Network Map

Oncology

Subspecialties: Urology - Immunology - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2005 - 2026
Source: PubMed

Ospedale di Parma

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 488

Citations

Citations: 6 278 1st author: 52 Last author: 74 Unique author: 2

Main journals

J Clin Oncol 71
Ann Oncol 42
Immunotherapy 20
Cancer Immunol Immunother 17
Clin Genitourin Cancer 17

Best Journals

J Clin Oncol 49
Ann Oncol 28
Lancet Oncol 6

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Global Disparities in the Availability and Reimbursement of Systemic Therapies for Renal Cell Carcinoma: Results of the International ARON-AID Survey.
PMID 42836687 — cells, radiation oncologists, oncologists, pharmaceutical preparations, neoplasms, income, carcinoma, renal cell, therapeutics		Oncologist20260
Sex-based analysis of first-line immune-based combinations in intermediate/poor-risk papillary, chromophobe, and unclassified renal cell carcinoma: an ARON-1 subanalysis.
PMID 42718726 — cells, carcinoma, renal cell, liver, neoplasm metastasis, histology, sex, therapeutics		Front Oncol20260
Molecular biomarkers in metastatic clear cell renal cell carcinoma treated with first-line immune combinations: a systematic review of phase III randomized clinical trials by Meet-URO group.
PMID 42645539 — cells, genes, carcinoma, renal cell, biomarkers, neoplasm metastasis, therapeutics		Cancer Metastasis Rev20260
Baseline Disease Characteristics and Platinum Sensitivity as Predictors of Outcomes in Sequential Therapy with Platinum-Based Chemotherapy, Avelumab Maintenance, and Enfortumab Vedotin in Advanced Urothelial Carcinoma (ARON-2EV Study).
PMID 42525332 — neoplasms, drug therapy, maintenance, therapeutics, chemotherapy		Target Oncol20260
PSMA PET in Lymph Node Staging of Prostate Cancer: From Diagnostic Accuracy to Clinical Decision-Making.
PMID 42449638 — lymph nodes, clinical decision-making, neoplasms, prostate, decision making, neoplasm metastasis, lymph, prostatic neoplasms, therapeutics		Cancers (Basel)20261

Clinical Studies 22

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 2 9
Phase 3 6
N/A 3
Phase 4 2
Phase 1/Phase 2 1
Phase 2/Phase 3 1

By status:

Recruiting 10
Completed 8
Unknown 3
Active not recruiting 1

By type:

Interventional 19
Observational 3

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 1
multicentric5to9 1
multicentricup10 15

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

10 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
CARE1 FIRST LINE RANDOMISED STUDY PLATFORM TO OPTIMIZE TREATMENT IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
2023-503317-29-00 — cells, carcinoma, renal cell, therapeutics, carcinoma		Phase 3Recruiting2024
A clinical study of belzutifan and zanzalintinib in people with advanced kidney cancer (MK 6482 033)
2024-517136-21-00 — cells, neoplasms, kidney, carcinoma, renal cell, respect, kidney neoplasms, therapeutics, carcinoma		Phase 3Recruiting2025
Phase 2 Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma
2023-505177-32-00 — cells, nephrectomy, metastasectomy, rna, messenger, carcinoma, renal cell, therapeutics, carcinoma		Phase 2Active not recruiting2024
Phase 2 3 Trial of Izalontamab Brengitecan vs Platinum based Chemotherapy for Metastatic Urothelial Cancer with Disease Progression on or After Immunotherapy
2025-522400-24-00 — neoplasms, disease progression, drug therapy, immunotherapy, therapeutics, chemotherapy		Phase 2/Phase 3Recruiting2026
CLINICAL AND HUMORAL IMPACT OF PRIMARY TUMOR ABLATION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH IMMUNOTHERAPY THE ITALIC RCC RANDOMIZED STUDY
2024-517789-41-00 — cells, neoplasms, carcinoma, renal cell, carcinoma		Phase 4Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS